Published on British Columbia Drug and Poison Information Centre (BC DPIC) (http://www.dpic.org)

Home > Increased risk of rhabdomyolysis with combined use of sodium fusidate and HMG-CoA reductase inhibitors > Increased risk of rhabdomyolysis with combined use of sodium fusidate and HMG-CoA reductase inhibitors

Increased risk of rhabdomyolysis with combined use of sodium fusidate and HMG-CoA reductase inhibitors

LEO Pharma Inc. has issued a "Dear Pharmacist" letter regarding a potentially serious drug interaction between Fucidin®  tablets and "statins" (HMG CoA-reductase inhibitors). Concurrent use of both medications can increase plasma concentrations of both drugs that may result in elevated creatine kinase levels. This could leak to pain, muscle weakness and rhabdomyolysis. Fucidin® inhibits CYP3A4. This could cause the statin level to increase and cause myocellular damage.

 

The company has received 49 cases of rhabdomyolysis or its associated symptoms from worldwide post-marketing surveillance repoorts through September 2008. None of these cases occurred in Canada.

 

If a patient has been prescribed both of these medications, they should consult their physician or pharmacist regarding therapy.

 

 

fusidic acid
hmg-coa reductase inhibitors
rhabdomyolysis

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh Úxwumixw (Squamish Nation), and səl̓ílwətaʔ (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.


© 2024 BC Drug and Poison Information Centre

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the full terms and conditions below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.
Terms and Conditions
Source URL (retrieved on 2025-04-19 08:54): http://www.dpic.org/content/increased-risk-rhabdomyolysis-combined-use-sodium-fusidate-and-hmg-coa-reductase-inhibitors